Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICD Settlements Raise Questions On Role Of NCDs As False-Claims Standard

This article was originally published in The Gray Sheet

Executive Summary

Attorneys who work on False Claims allegations are pleased by the $250 million settlement on ICDs installed outside Medicare coverage policy, but electrophysiologists say the policy is out of date. But it's not clear that national coverage determinations will be a frequent source of false-claims suits in other device sectors.

You may also be interested in...



51 More Hospitals Join Federal ICD Settlement

The Department of Justice says the additional 51 hospitals that settled with the government on charges of billing for ICD implants outside of Medicare coverage guidelines represent the "final stage" of a long-running investigation. DoJ previously identified another 457 hospitals that have settled. Hospitals payments tied to the investigation total $273 million.

Hospitals Settle Federal Allegations Of ICDs Implanted Afoul Of Medicare Policy

More than 400 hospitals settled with the Justice Department following a five-plus year investigation into ICD implants performed during post-heart attack and post-surgery periods when Medicare policy states the devices generally should not be put in.

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel